Holen Sie sich die Stockscreener-App
55.23
1.65%
-1.0619
Schlusskurs vom Vortag:
$56.29
Offen:
$56.26
24-Stunden-Volumen:
524.48K
Relative Volume:
0.21
Marktkapitalisierung:
$10.62B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
20.53
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+5.33%
1M Leistung:
+1.62%
6M Leistung:
-3.81%
1J Leistung:
-14.67%
1-Tages-Spanne:
$54.80
$56.26
1-Wochen-Bereich:
$52.36
$56.45
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.29 | 10.81B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.80 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.95 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.67 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
925.62 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.55 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks - Finviz
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Finviz
Will BioMarin Pharmaceutical Inc. (BM8) stock beat revenue estimatesWeekly Trend Summary & Comprehensive Market Scan Insights - newser.com
How BioMarin Pharmaceutical Inc. (BM8) stock responds to bond marketTrade Exit Report & Weekly High Conviction Trade Ideas - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock outperform global peersMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Will BioMarin Pharmaceutical Inc. (BM8) stock attract long term capital inflowsJuly 2025 Technicals & Verified Momentum Stock Watchlist - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap vs fundamentalsCEO Change & AI Enhanced Market Trend Forecasts - newser.com
How higher bond yields impact BioMarin Pharmaceutical Inc. (BM8) stock2025 Fundamental Recap & Fast Gain Swing Trade Alerts - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecasts2025 Key Lessons & Fast Gain Stock Tips - newser.com
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Will BioMarin Pharmaceutical Inc. stock split attract more investors - newser.com
Key resistance and support levels for BioMarin Pharmaceutical Inc.CEO Change & Consistent Profit Trade Alerts - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for BioMarin Pharmaceutical Inc. stock2025 Price Action Summary & Weekly Stock Performance Updates - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Risk Controlled Swing Alerts - newser.com
Biomarin Pharmaceutical Inc (BM8.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
How currency fluctuations impact BioMarin Pharmaceutical Inc. stockJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):